Low density lipoprotein apheresis in treatment of hyperlipidemia: Experience with four different technologies

Therapeutic Apheresis

Volumn 4, Issue 3, 2000, Pages 213-217

  Bambauer, Rolf ^a   Schiel, Ralf ^a   Latza, Reinhard ^a  

^a Institute for Blood Purification   (Germany)

Author keywords

Cholesterol; Coronary heart disease; Hyperlipidaemia; Low density lipoprotein apheresis; Triglycerides

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTILIPEMIC AGENT; BEZAFIBRATE; COLESTIPOL; COLESTYRAMINE; DEXTRAN SULFATE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ALLERGIC REACTION; ANGINA PECTORIS; APHERESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY BYPASS GRAFT; DIET; FEMALE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; SHOCK;

ADULT; ANGINA PECTORIS; BLOOD COMPONENT REMOVAL; CHOLESTEROL; CORONARY DISEASE; FEMALE; HUMANS; HYPERLIPIDEMIAS; IMMUNOSORBENT TECHNIQUES; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0033922444     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2000.00180.x     Document Type: Conference Paper

References (29)

1. Report of the working group of arteriosclerosis of the national heart, lung, and blood institute, Washington. Government Printing Office, 2. Dept. of Health Education and Welfare Publication No. (NIH) 82-2035, 1982.
2. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (The PROCAM experience). Am J Cardiovasc 1992;70:733-7.
3. Heinonen OP, Huttunen JK, Manninen V, Manttari M, Koskinen P, Tenkanen L, Frick MH. The Helsinki Heart Study: Coronary heart disease incidence during extended follow-up. J Intern Med 1994;235:41-9.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Mac-Farlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
6. Sachs FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-9.
7. Editorial. Design, rational, and baseline characteristics of the prospective pravastatin pooling (PPP) project - a combined analysis of three large-scale randomized trials: Long-term intervention with pravastatin in ischemic disease (LIPID), cholesterol and recurrent events (CARE), and West of Scotland coronary prevention study (WOSCOPS). Am J Cardiol 1995; 76:899-905.
8. Thompson GR, Kitano Y. The role of low-density lipoprotein apheresis in the treatment of familiar hypercholesterolemia. Ther Apher 1997;1:13-6.
9. Schiel R, Bambauer R, Müller UA. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis. Int J Artif Organs 1995;18: 786-93.
10. Bambauer R, Schiel R, Latza R, Klinkmann J, Schneidewind JM. LDL apheresis in clinical practice: Long-term treatment of severe hyperlipidemia. Ther Apher 1997;1:49-54.
11. Yamamoto T, Yamahita T. Low-density lipoprotein apheresis using the Liposorber system: Features of the system and clinical benefits. Ther Apher 1998;2:25-30.
12. Kanemitsu S, Takekoshi N, Matsui S, Tsugawa H, Ohkubo S, Kitayama M, Matsuda T, Senma J, Masuyama K, Yamagata T, Murakami E. Short-term and long-term effects of low-density lipoprotein (LDL) apheresis on restenosis after percutaneous transluminal coronary angioplasty (PTCA): Is lowering Lp(a) by LDL apheresis effective on restenosis after PTCA? Ther Apher 1998;2:65-70.
13. Study Group European Atherosclerosis Society. Strategies for the prevention of coronary heart disease: A policy statement of the European Atherosclerosis Society. Eur Heart J 1987;8:77-88.
14. Rose GA, Blackburn H. Cardiovascular survey methods. WHO-Monogr Ser 1968;56:137-54.
15. Cook DG, Shaper AG, McFarlane PW. Using the WHO (Rose) angina questionnaire in cardiovascular epidemiological studies, Int J Epidemiol 1989;18:607-13.
16. World Health Organization Expert Committee. Second report on diabetes mellitus. World Health Organization technical report series No. 646. Geneva, Switzerland, 1980.
17. Apstein CS, Zilversmith DB, Lees RS, George PK. Effect of intensive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemia. Atherosclerosis 1978;31:105-15.
18. Agishi T, Wood W, Gordon B. LDL apheresis using the Liposorber® LA-15 system in coronary and peripheral vascular disease associated with severe hypercholesterolemia. Curr Ther Res 1994;55:879-904.
19. Bosch T, Seidel D, Gurland HJ. Efficacy of lipid apheresis: Definitions and influencing factors. Int J Artif Organs 1995; 18:210-15.
20. Friedwald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
21. Sloop GD. A critical analysis of the role of cholesterol in atherogenesis. Atherosclerosis 1999;142:265-8.
22. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340:115-126.
23. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
24. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
25. Levine GN, Keancy JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995;332:512-21.
26. Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC, Diensenbacher A, Eisenhauer T, Grützmacher P, Keller C, Kettner U, Kleophas W, Köster W, Olbricht CJ, Richter WO, Seidel D and the HELP-Study Group. The HELP-LDL-apheresis multicenter study, an angiographically assessed trial on the role of LDL apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest 1994;24:724-32.
27. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999;103:747-53.
28. Witztum JL, Palinski W. Are immunological mechanisms relevant for the development of atherosclerosis? Clin Immunol 1999;90:153-6.
29. Shimokawa H. Primary endothelial dysfunction: Atherosclerosis. J Mol Cell Cardiol 1999;31:23-37.